000 01819nam  2200373zi 4500
0019.935111
003CaOODSP
00520240403125521
006m     o  d f      
007cr mn|||||||||
008240308e20240306onc     ob   f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH113-27/2024-2E-PDF
24500|aNatamycin and its associated end-use products : |bconsultation document.
264 1|aOttawa, Ontario : |bPest Management Regulatory Agency, Health Canada, |c6 March 2024.
264 4|c©2024
300 |a1 online resource (10 pages).
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
4901 |aProposed re-evaluation decision, |x1925-0967 ; |vPRVD2024-02
500 |aIssued also in French under title: Natamycine et préparations commerciales connexes : document de consultation.
504 |aIncludes bibliographical references.
650 0|aAntifungal agents|xCertification|zCanada.
650 0|aAntifungal agents|xRisk assessment|zCanada.
650 0|aAntifungal agents|xHealth aspects.
650 0|aAntifungal agents|xEnvironmental aspects.
7101 |aCanada. |bPest Management Regulatory Agency, |eissuing body.
77508|tNatamycine et préparations commerciales connexes : |w(CaOODSP)9.935112
830#0|aProposed re-evaluation decision (Canada. Pest Management Regulatory Agency)|vPRVD2024-02.|w(CaOODSP)9.505201
85640|qPDF|s280 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/h113-27/H113-27-2024-2-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/consumer-product-safety/pesticides-pest-management/public/consultations/proposed-re-evaluation-decisions/2024/natamycin/document.html